Acute cardiac care & resuscitation
Milrinone vs Dobutamine for the Management of Cardiogenic Shock: Implications of Renal Function and Injury
Authors' conclusion
A modulating effect of AKI on the relative efficacy of milrinone compared to dobutamine was observed, characterized by attenuation of a potential clinical benefit with milrinone compared to dobutamine in patients who develop AKI.
Study context
- Population
- Patients requiring inotropic support for cardiogenic shock, stratified by baseline estimated glomerular filtration rate (eGFR) 60 ml/min/1.73 m² and acute kidney injury (AKI)
- Comparison
- Milrinone vs dobutamine, by baseline eGFR and AKI
- Primary endpoint
- Composite of:
- In-hospital all-cause death
- Resuscitated cardiac arrest
- Cardiac transplant or mechanical circulatory support
- Nonfatal MI
- TIA or stroke
- Initiation of renal replacement therapy
- Follow-up
- In-hospital
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
As reported in the abstract
Treatment effect by renal function subgroup
- Interaction of treatment effect with AKI, primary outcome
- P interaction = 0.02
- Interaction of treatment effect with AKI, death
- P interaction = 0.04
Further findings
Prevalence of renal dysfunction
- Baseline eGFR <60 ml/min/1.73 m²
- 78 (45%)
- AKI
- 124 (65%)
Overall event rates
- Primary outcome
- 99 (52%)
- Death from any cause
- 76 (40%)
Original publication
Milrinone vs Dobutamine for the Management of Cardiogenic Shock: Implications of Renal Function and Injury. JACC Adv. Published 5 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →